AlphaYou
Overview
Smart money at a glance
Filings to Sep 27, 2026Net selling: insiders sold $10.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$10.6M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- 10+ awardsAwards on record
Key stats
Fundamentals Sep 26- Open
- $61.33
- 52-wk high
- $65.19
- High
- $65.19
- 52-wk low
- $13.95
- Low
- $60.51
- Prev close
- $61.37
- Mkt cap
- $3.17B
- P/E
- 26.1x
- Volume
- 2.35M
- Fwd P/E
- 156.3x
- Beta
- 2.43
- P/S
- 6.9x
- P/B
- 6.6x
- Profit margin
- +24.2%
- Op margin
- +0.2%
- ROE
- +29.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CDNA filings
Are insiders buying or selling CareDx Inc (CDNA) stock?
Net selling: insiders sold $10.6M and bought $0 of CDNA stock on the open market in the 90 days to Sep 27, 2026, according to SEC Form 4 filings. $7.5M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Hanna, John Walter JR (President and CEO), who sold $5.6M. The latest filing was on Aug 6, 2026.
Which members of Congress have traded CDNA recently?
None. No member of Congress disclosed a CDNA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CDNA smart-money data?
This summary uses filings available on Sep 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What insiders are doing
How top traders are positioned
No tracked top-trader positions in CDNA right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in $0.11 a share above what analysts expected.
Earnings per share
$0.06 expected
Reports Nov 3, 2026, in 37 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $100.1M | $108.4M | $117.7M | $131.9M |
| Cost of what it sold | $30.7M | $35.5M | $33.6M | $35.0M |
| Gross profit | $69.4M | $72.9M | $84.1M | $97.0M |
| What it spent | ||||
| Research and development | $16.8M | $19.3M | $21.4M | $22.4M |
| Sales and admin | $28.4M | $28.7M | $30.5M | $40.9M |
| Other operating costs | $24.4M | $30.9M | $30.4M | $33.4M |
| Total operating expenses | $69.6M | $78.9M | $82.3M | $96.7M |
| What was left | ||||
| Operating profit | -$246.0K | -$6.0M | $1.8M | $257.0K |
| Profit before tax | $1.7M | -$3.8M | $2.8M | $114.5M |
| Tax | -$15.0K | $345.0K | -$32.0K | $3.9M |
| Net profit | $1.7M | -$4.1M | $2.8M | $110.6M |
| EBITDA | $4.9M | -$780.0K | $7.1M | $4.3M |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace